155 related articles for article (PubMed ID: 2385604)
1. Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.
Bergerat JP; Ford J; Herbrecht R; Dufour P; Oberling F; Jacqmin D; Bollack C; Prevot G; Salze P; Jurascheck F
Prog Clin Biol Res; 1990; 348():137-50. PubMed ID: 2385604
[No Abstract] [Full Text] [Related]
2. Interferons in renal-cell carcinoma: status and prospects.
De Mulder PH; Debruyne FM; Beniers AJ
Prog Clin Biol Res; 1990; 348():49-59. PubMed ID: 1696737
[No Abstract] [Full Text] [Related]
3. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
[No Abstract] [Full Text] [Related]
4. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F
J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838
[TBL] [Abstract][Full Text] [Related]
5. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
6. Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.
Otto U; Schneider AW; Conrad S; Klosterhalfen H
Prog Clin Biol Res; 1990; 350():275-82. PubMed ID: 2117287
[No Abstract] [Full Text] [Related]
7. New prospects in the management of metastatic renal cell carcinoma. Experimental and clinical data.
Debruyne FM; Franssen MP; Beniers AJ; Schalken JA; de Mulder PH
Prog Clin Biol Res; 1990; 350():243-55. PubMed ID: 2117284
[No Abstract] [Full Text] [Related]
8. Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma?
Merimsky O; Shnider BI; Chaitchik S
Mol Biother; 1991 Mar; 3(1):34-7. PubMed ID: 2069758
[TBL] [Abstract][Full Text] [Related]
9. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
Hernberg M; Muhonen T; Pyrhönen S
Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
[TBL] [Abstract][Full Text] [Related]
10. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Figlin RA; deKernion JB; Maldazys J; Sarna G
Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
[TBL] [Abstract][Full Text] [Related]
11. Cyclic interferon gamma application in patients with renal cell carcinoma.
Grups JW; Frohmüller HG
Prog Clin Biol Res; 1990; 350():257-62. PubMed ID: 2117285
[No Abstract] [Full Text] [Related]
12. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
13. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
Huland E; Heinzer H; Huland H
Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
[TBL] [Abstract][Full Text] [Related]
14. [Effect of kidney occlusion on survival in renal cell carcinoma: a 10-year retrospective study].
Latal D; Kautzky W; Wanek R; Kumpan W
Z Urol Nephrol; 1990 Jan; 83(1):27-31. PubMed ID: 2330762
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy using tumor-infiltrating lymphocytes.
Figlin RA
Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
[No Abstract] [Full Text] [Related]
16. Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma.
Uygur MC; Usubütün A; Ozen H; Ayhan A; Kendi S
J Exp Clin Cancer Res; 1999 Sep; 18(3):397-401. PubMed ID: 10606187
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma.
Merimsky O; Inbar M; Merimsky E; Kovner F; Spitzer E; Laufer R; Braf Z; Chaitchik S
Mol Biother; 1990 Sep; 2(3):155-9. PubMed ID: 2222899
[TBL] [Abstract][Full Text] [Related]
19. [The medical treatment of renal cancer in adults].
Sculier JP
Rev Med Brux; 1989 May; 10(5):190-6. PubMed ID: 2662317
[TBL] [Abstract][Full Text] [Related]
20. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
